143540-05-0

Basic information

• Product Name: 2-(Hydroxymethyl)-1,4-piperazinedicarboxylic acid 1,4-bis(tert-butyl) ester
• Synonyms: 2-(Hydroxymethyl)-1,4-piperazinedicarboxylic acid 1,4-bis(tert-butyl) ester;1,4-DI-BOC-2-(HYDROXYMETHYL)PIPERAZINE;1,4-Di-Boc-2-(hydroxyMethyl);Di-tert-butyl 2-(hydroxymethyl)-piperazine-1,4-dicarboxylate;1,4-Bis(Boc)-2-piperazinemethanol;1,4-Piperazinedicarboxylic acid, 2-(hydroxymethyl)-, 1,4-bis(1,1-dimethylethyl) ester
• CAS NO: 143540-05-0
• Molecular Formula: C₁₅H₂₈N₂O₅
• Molecular Weight: 316.39322
• Mol File: 143540-05-0.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 406.9±20.0 °C(Predicted)
• Appearance: /
• Density: 1.123
• Storage Temp.: 2-8°C
• Solubility: Chloroform (Slightly), Methanol (Slightly)
• PKA: 14.97±0.10(Predicted)
• CAS DataBase Reference: 2-(Hydroxymethyl)-1,4-piperazinedicarboxylic acid 1,4-bis(tert-butyl) ester(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(Hydroxymethyl)-1,4-piperazinedicarboxylic acid 1,4-bis(tert-butyl) ester(143540-05-0)
• EPA Substance Registry System: 2-(Hydroxymethyl)-1,4-piperazinedicarboxylic acid 1,4-bis(tert-butyl) ester(143540-05-0)

Safety Data

• Hazardous Substances Data: 143540-05-0(Hazardous Substances Data)

Usage

Uses

Di-tert-butyl 2-(Hydroxymethyl) Piperazine-1,4-dicarboxylate is a useful compound for the preparation of the LSD1 inhibitor.

Upstream product

• 28795-50-8 2-hydroxymethylpiperazine 
• 24424-99-5 di-tert-butyl dicarbonate 
• 181955-79-3 N,N'-di-tert-butyloxycarbonylpiperazine-2-carboxylic acid 
• 543-27-1 isobutyl chloroformate 
• 13292-87-0 dimethyl sulfide borane 
• 171504-98-6 O₁,O₄-di-tert-butyl O₂-methyl piperazine-1,2,4-tricarboxylate 

Downstream Products

• 935544-47-1 tert-butyl 3-oxotetrahydro-1H-oxazolo[3,4-a]pyrazine-7(3H)-carboxylate 
• 1372679-65-6 hexahydro-2-(3-fluorobenzyl)-imidazo[1,5-a]pyrazin-3-one 
• 1372679-49-6 tert-butyl 2-(3-fluorobenzyl)-hexahydro-3-oxoimidazo[1,5-a]pyrazine-7(1H)-carboxylate 
• 1372679-57-6 hexahydro-2-(4-nitrophenyl)-imidazo[1,5-a]pyrazin-3-one 
• 1372679-41-8 tert-butyl 2-(4-nitrophenyl)-hexahydro-3-oxoimidazo[1,5-a]pyrazine-7(1H)-carboxylate 
• 1002339-44-7 tert-butyl 2-(4-(methylsulfonyl)phenyl)-hexahydro-3-oxoimidazo[1,5-a]pyrazine-7(1H)-carboxylate 
• 1256816-01-9 tert-butyl 2-(4-cyanophenyl)-hexahydro-3-oxoimidazo[1,5-a]pyrazine-7(1H)-carboxylate 
• 1002338-92-2 tert-butyl 2-(4-chlorophenyl)-hexahydro-3-oxoimidazo[1,5-a]pyrazine-7(1H)-carboxylate 
• 1256816-00-8 tert-butyl 2-(4-fluorophenyl)-hexahydro-3-oxoimidazo[1,5-a]pyrazine-7(1H)-carboxylate 
• 1256815-96-9 tert-butyl 2-(3-cyanobenzyl)-hexahydro-3-oxoimidazo[1,5-a]pyrazine-7(1H)-carboxylate 
• 1256815-92-5 tert-butyl 2-(4-methoxybenzyl)-hexahydro-3-oxoimidazo[1,5-a]pyrazine-7(1H)-carboxylate 
• 1256815-91-4 tert-butyl 2-(4-chlorobenzyl)-hexahydro-3-oxoimidazo[1,5-a]pyrazine-7(1H)-carboxylate 
• 1256815-90-3 tert-butyl 2-(4-methylbenzyl)-hexahydro-3-oxoimidazo[1,5-a]pyrazine-7(1H)-carboxylate 
• 1256815-89-0 tert-butyl 2-(4-fluorobenzyl)-hexahydro-3-oxoimidazo[1,5-a]pyrazine-7(1H)-carboxylate 

Relevant articles and documents

Application of piperazine structure containing compound to preparation of LSD1 (Lysine Specific Demethylase 1) inhibitor

The invention discloses application of a piperazine structure containing compound to the preparation of a histone lysine specific demethylase (LSD1) inhibitor. The structural general formula of the compound is as shown in the following descriptions (wherein, A is hydrogen, carbonyl or thiocarbonyl) or a configurational isomer and a pharmaceutical salt thereof, or is as shown in the following descriptions or a pharmaceutical salt thereof. The compound has an obvious inhibition effect on the LSD1, can be prepared into the LSD1 inhibitor, and is used for preventing and treating a disease related to the activity of the histone LSD1.

Tricyclic heterocyclic compound and use thereof

The present invention provides a tricyclic heterocyclic compound having a serotonin 5-HT2C receptor activation action and the like. A 5-HT2C receptor activator containing a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof or a prodrug thereof.

NOVEL PIPERAZINES, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF

Disclosed are novel piperazine derivatives that act as agonists of the α7 nAChR. Also disclosed are phannaceutical compositions, methods of treating inflammatory conditions, methods of treating CNS disorders, methods for inhibiting cytokine release from mammalian cells and methods for the preparation of the novel compounds.